NASDAQ:AGIO Agios Pharmaceuticals (AGIO) Stock Price, News & Analysis $40.00 +0.35 (+0.88%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$39.99 -0.01 (-0.02%) As of 07/25/2025 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Agios Pharmaceuticals Stock (NASDAQ:AGIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Agios Pharmaceuticals alerts:Sign Up Key Stats Today's Range$38.82▼$40.1350-Day Range$29.59▼$40.5652-Week Range$23.42▼$62.58Volume529,138 shsAverage Volume646,375 shsMarket Capitalization$2.32 billionP/E Ratio3.56Dividend YieldN/APrice Target$57.33Consensus RatingModerate Buy Company Overview Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Read More Agios Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreAGIO MarketRank™: Agios Pharmaceuticals scored higher than 87% of companies evaluated by MarketBeat, and ranked 129th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingAgios Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAgios Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Agios Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Agios Pharmaceuticals are expected to grow in the coming year, from ($6.85) to ($5.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agios Pharmaceuticals is 3.56, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.98.Price to Earnings Ratio vs. SectorThe P/E ratio of Agios Pharmaceuticals is 3.56, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.07.Price to Book Value per Share RatioAgios Pharmaceuticals has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Agios Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.83% of the float of Agios Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAgios Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Agios Pharmaceuticals has recently decreased by 12.50%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAgios Pharmaceuticals does not currently pay a dividend.Dividend GrowthAgios Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.13 Percentage of Shares Shorted6.83% of the float of Agios Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAgios Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Agios Pharmaceuticals has recently decreased by 12.50%, indicating that investor sentiment is improving significantly. News and Social Media2.0 / 5News Sentiment0.57 News SentimentAgios Pharmaceuticals has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.06 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Agios Pharmaceuticals this week, compared to 6 articles on an average week.MarketBeat Follows1 people have added Agios Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,619,654.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Agios Pharmaceuticals is held by insiders.Read more about Agios Pharmaceuticals' insider trading history. Receive AGIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AGIO Stock News HeadlinesDavid Scadden Sells 1,400 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) StockJuly 16, 2025 | insidertrades.comInsider Selling: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sells 4,091 Shares of StockJuly 4, 2025 | insidertrades.comHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation. | Paradigm Press (Ad)Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CFO Cecilia Jones Sells 1,780 SharesJune 27, 2025 | insidertrades.comAgios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ETJuly 14, 2025 | globenewswire.comAgios pharma chief medical officer Gheuens sells $452,601 in stockJuly 13, 2025 | investing.comAgios Pharmaceuticals Shows Improved Relative Price Performance; Still Shy Of BenchmarkJuly 10, 2025 | msn.comAgios Pharmaceuticals (AGIO) Moves 7.7% Higher: Will This Strength Last?July 10, 2025 | msn.comSee More Headlines AGIO Stock Analysis - Frequently Asked Questions How have AGIO shares performed this year? Agios Pharmaceuticals' stock was trading at $32.86 at the beginning of the year. Since then, AGIO shares have increased by 21.7% and is now trading at $40.00. How were Agios Pharmaceuticals' earnings last quarter? Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) released its earnings results on Thursday, May, 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping the consensus estimate of ($1.80) by $0.25. The biopharmaceutical company had revenue of $8.73 million for the quarter, compared to analysts' expectations of $9.86 million. Agios Pharmaceuticals had a net margin of 1,798.26% and a negative trailing twelve-month return on equity of 2.75%. Read the conference call transcript. Who are Agios Pharmaceuticals' major shareholders? Top institutional investors of Agios Pharmaceuticals include Oak Ridge Investments LLC (0.06%), Harbor Capital Advisors Inc. (0.06%), KLP Kapitalforvaltning AS (0.02%) and CWM LLC (0.01%). Insiders that own company stock include Jacqualyn A Fouse, Brian Goff, Sarah Gheuens, Cecilia Jones, James William Burns, Tsveta Milanova, David Scadden, Kaye I Foster-Cheek and Theodore James Jr Washburn. View institutional ownership trends. How do I buy shares of Agios Pharmaceuticals? Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Agios Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Agios Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), AU Optronics (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings5/01/2025Today7/25/2025Next Earnings (Estimated)7/31/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AGIO CIK1439222 Webwww.agios.com Phone(617) 649-8600FaxN/AEmployees390Year FoundedN/APrice Target and Rating Average Price Target for Agios Pharmaceuticals$57.33 High Price Target$71.00 Low Price Target$51.00 Potential Upside/Downside+43.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$11.24 Trailing P/E Ratio3.56 Forward P/E RatioN/A P/E GrowthN/ANet Income$673.72 million Net Margins1,798.26% Pretax Margin1,917.72% Return on Equity-2.75% Return on Assets-2.52% Debt Debt-to-Equity RatioN/A Current Ratio18.50 Quick Ratio17.93 Sales & Book Value Annual Sales$36.50 million Price / Sales63.47 Cash FlowN/A Price / Cash FlowN/A Book Value$27.02 per share Price / Book1.48Miscellaneous Outstanding Shares57,920,000Free Float55,425,000Market Cap$2.32 billion OptionableOptionable Beta0.73 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:AGIO) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agios Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.